ClinicalTrials.gg
Not yet recruitingNCT07314567Updated Jan 2, 2026

ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

An interventional study of ACE1831 and Lymphodepleting chemotherapy in System Lupus Erythematosus(SLE), sponsored by Tongji Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Tongji Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
153rd of 245
22 · median 36
Started
2026
with 55 others
No phase
32 of 266
21 open now
Primary completion
2027-10
later than 119 of 190 live
Registered
208th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 153rd largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 32 with no phase, reaches primary completion later than 119 of the 190 other live ones, and was the 208th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Relapsed/Refractory Systemic lupus erythematosus (SLE)

03

Conditions studied

  • System Lupus Erythematosus(SLE)

Keywords

  • ACE1831
  • SLE
  • Refractory Systemic lupus erythematosus (SLE)
  • gamma delta T (gdT) cell
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 to 60 years (inclusive)
  • History of meeting the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria, or the 1997 ACR criteria, or the 2012 Systemic Lupus International Collaborating Clinics (SLICC)
  • Presence of anti-dsDNA antibodies and/or anti-nuclear antibodies (ANA) and/or anti-Smith (anti-Sm) antibodies positive
  • SLE is in the moderate to severe active phase with the SLEDAI-2000 score ≥ 8
  • At least one British Isle Lupus Rating Group Index (BILAG-2004) Class A (severe manifestation) or two Class B (moderate manifestation) organ scores, or both
  • Inadequate response to and at least 2 of treatments used for at least 3 months
  • Women of and their partners must agree to use at least 1 highly effective method of throughout the study period and for 1 year after treatment
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Severe lupus nephritis requiring prohibited medications for active nephritis treatment,or hemodialysis, or \< 50 ml/min/1.73m²
  • Central nervous system disease caused by SLE or other conditions
  • Significant medical history that would pose a risk to the patients safety from the investigator's opinion, or patients medical condition could worsen during the study
  • within 5 years
  • Presence of active, recurrent, chronic infection requiring treatment , or latent infection (, , , TB, syphilis)
  • Received any B-cell depletion biologic therapy
  • Received small molecule drug therapy, or other systemic therapy , or prednisone
  • Pregnant or lactating women
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Participant

    The single, open label study arm includes 2 dose escalation cohorts: Cohort 1: Receives ACE1831 (Dose Level 1) with LDC depending on assignment Cohort 2: Receives ACE1831 (Dose Level 2) with LDC depending on assignment

    Drug: ACE1831 · Drug: Lymphodepleting chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of ACE1831 in subjects with Refractory Systemic lupus erythematosus

    To assess the incidence of Adverse Events (AEs), \[AEs including Treatment Emergent AEs, Serious AEs (SAEs), AEs of Special Interests (AESIs), and dose limiting toxicities (DLTs)\] (unit: number of AEs)

    Time frame: 24 weeks after last dose of ACE1831

Secondary outcomes

  1. To assess the efficacy of ACE1831: Changes in SLE disease activity Index (SLEDAI-2000) score

    Changes of SLE disease activity Index (SLEDAI-2000) score

    Time frame: 24 weeks after last dose of ACE1831

  2. To assess the efficacy of ACE1831 (secondary efficacy):Changes in PGA

    Changes in Physician's Global Assessment (PGA) of disease activity score (Visual Activity Score,scale range 0 - 100)

    Time frame: 24 weeks after last dose of ACE1831

  3. To assess the efficacy of ACE1831 : Changes in SGA

    Changes in Subject's Global Assessment (SGA) of disease activity score (Visual Activity Score,scale range 0 - 100)

    Time frame: Time Frame: 24 weeks after last dose of ACE1831

  4. To assess the efficacy of ACE1831 :Changes in LupusQOL

    Changes of Lupus Qualituy of Life(LupusQOL) total score

    Time frame: 24 weeks after last dose of ACE1831

  5. To assess the efficacy of ACE1831 :Changes in EQ-5D-5L score

    Changes of European Quality of Life Five Dimension Five Level questionnaire(EQ-5D-5L )score

    Time frame: 24 weeks after last dose of ACE1831

  6. To assess the efficacy of ACE1831 :Changes in SF-12 score

    Changes in Quality of Life Questionnaire (QOL) Short Form 12 (SF-12) total score

    Time frame: 24 weeks after last dose of ACE1831

  7. To assess the efficacy of ACE1831 :Changes in BILAG-2004 score

    Changes of BILAG-2004 score

    Time frame: 24 weeks after last dose of ACE1831

  8. To assess the efficacy of ACE1831: LLDAS rate

    Proportions of subjects achieving LLDAS by timepoint

    Time frame: 24 weeks after last dose of ACE1831

  9. To assess the efficacy of ACE1831: DORIS

    Proportions of subjects who achieved remission according to the DORIS by timepoint

    Time frame: 24 weeks after last dose of ACE1831

  10. To assess the efficacy of ACE1831: SRI-4 response rate

    Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response

    Time frame: 24 weeks after last dose of ACE1831

  11. Persistence of ACE1831 after administration

    Half-life of ACE1831

    Time frame: 8 weeks after last dose of ACE1831

  12. Measure the pharmacodynamics change of ACE1831

    Immunoglobulin, cytokines, lymphocytecount , autoantibody titers, complement C3 and C4 levels, C-reactive protein, erythrocyte sedimentation rate, etc

    Time frame: 24 weeks after last dose of ACE1831

  13. Immunogenicity

    Titration of anti-ACE1831 antibodies after administration

    Time frame: 24 weeks after last dose of ACE1831

Other outcomes

  1. To assess the efficacy of ACE1831: single-cell sequencing

    Time frame: 24 weeks after last dose of ACE1831

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Oct 2027, 21 months later.

Of 123 non-industry interventional studies with no phase under Lupus Erythematosus, Systemic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 21 months is close to that.

Counting every sponsor, half of 130 studies reached it within 23 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Jan 2, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07314567
Lead sponsor
Tongji Hospital
Responsible party
Lingli Dong (Director of the department of rheumatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tongji Hospital) — Principal investigator
First posted
Jan 2, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Oct 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 2, 2026

Study contacts

Lingli Dong
Contact
tjhdongll@163.com
+862783665519
Ziwei Hu
Contact
836048368@qq.com
13237100403

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831

Start the discussion